Pfizer Inc

Company facts

Industry

Pharmaceutical Preparations

Headquarters

New York, New York

Most recent report

10-Q, filed Aug 4, 2026

Incorporated

Delaware

Filings on record

1,001+ filings

On EDGAR

CIK 78003

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Jun 2026 10-Q

SECSift found 2 of 11 sections worth reading, with 0 positive, 8 notable, and 3 negative flags.

• Financial Statements (Item 1)

  Full financials and notes with large impairments, ViiV sale, restructuring programs, legal settlements.
  Notable

  • Restructuring programs expanded: total cost expected to reach ~$12.7B, including new $4B phase.
  • Settled Vyndaqel/Vyndamax patent litigations; generic entry permitted June 1, 2031.

• Management's Discussion (Item 2)

  MD&A contains detailed financial results, segment performance, and material risk updates.
  Notable

  • Realigning Our Cost Base Program: additional $1.0B savings announced, total now $6.7B through 2029.
  • Manufacturing Optimization Program: additional $1.5B savings announced, total now $3.0B through 2029.
  • Innovent collaboration: $650M upfront, up to $9.85B milestones for 12 early-stage cancer drugs.
  • Section 232 tariffs zero for Pfizer until Jan 20, 2029 after final binding agreements with U.S. government.
  • No share repurchases in first six months of 2026; remaining authorization $3.3B.
  • Pfizer sold its 11.7% ViiV investment for $1.875B in cash, recorded as a net gain.
  Negative

  • Patent exclusivity revenue impact in 2026 now expected $1.1B, down from prior $1.5B but still significant.
  • Oxbryta: no viable pathway to return to U.S. market; Pfizer voluntarily withdrawing NDAs.
  • Sigvotatug vedotin Phase 3 study in NSCLC failed to meet primary survival endpoint.

What changed: Jun 2026 vs. Mar 2026

About 18% of PFE's Jun 2026 10-Q is new information. 106 paragraphs were added, 156 changed, and 47 removed. Below are the most important lines SECSift identified.

• Item 2 99
• Item 1 98
• Item 5 8
• Item 6 1